Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative)

v3.20.1
Subsequent Events (Details Narrative) - USD ($)
 3 Months Ended
Apr. 20, 2020
Mar. 31, 2020
Mar. 31, 2019
Payments for consulting   $ 98,223 $ 140,029
License Agreement [Member] | QSAM Therapeutics Inc [Member]      
Agreement term description The License Agreement is for 20 years or until the expiration of the multiple patents covered under the license, and requires multiple milestone based payments including: $60,000 and other expense reimbursements within 60 days of signing, up to $150,000 as the Technology advances through multiple stages of clinical trials, and $1.5 million upon commercialization. IGL will also receive equity in QSAM equal to 5% of the company to be issued within 60 days of signing. Upon commercialization, IGL will receive an on-going royalty equal to 4.5% of Net Sales, as defined in the License Agreement, and up to 50% of any Sublicense Consideration received by QSAM, as defined in the License Agreement.    
Other expense reimbursements $ 60,000    
Payments for commercialization $ 1,500,000    
Equity ownership percentage 5.00%    
Royalty percentage 4.50%    
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]      
Advances for technology $ 150,000    
Royalty percentage 50.00%    
License Agreement [Member] | IGL Pharma Inc [Member]      
Equity ownership percentage 25.00%    
Two-Year Consulting and Confidentiality Agreement [Member] | IGL Pharma Inc [Member]      
Payments for consulting $ 8,500